Pulmonary Medicine Patiala

15/04/2021

https://www.facebook.com/watch/?v=1768433403335633

14/01/2015

http://chestgmcpatiala.weebly.com/lohri-celebration.html

Department Of Pulmonary Medicine

31/12/2014

Happy new year 😄

20/02/2014

COPD 2014 Update

http://www.goldcopd.org/uploads/users/files/GOLD_Report2014_Feb07.pdf

12/09/2013

05/09/2013

Teachers Day

30/08/2013

Tuberculosis Update

07/08/2013

Spotter1
A fifteen-year-old boy was investigated for failure to thrive. He was totally asymptomatic and no respiratory complaint at the time of evaluation. He had received two courses of anti tuberculosis treatment (2007 and 2009) elsewhere with the diagnosis of Miliary tuberculosis based on radiological findings. Clinical examination did not reveal any abnormality.
His CBC, electrolytes and calcium were normal. Ultrasound of abdomen was normal. Flow volume loop showed mild restriction. Serial chest X-rays from 2007 showed bilateral diffuse micronodular calcific shadows more toward the mid and lower zones .HRCT scan showed bilateral diffuse micronodular opacities distributed predominantly over basal and posterior regions with thickening of interlobar septa.

07/08/2013

Spot the diagnosis...

18/06/2013

Moxonidine :new-generation centrally-acting antihypertensive drug licensed for the treatment of mild to moderate essential hypertension.
is a selective agonist at the imidazoline receptor subtype 1 (I1). This receptor subtype is found in both the rostral ventro-lateral pressor and ventromedial depressor areas of the medulla oblongata. Moxonidine therefore causes a decrease in sympathetic nervous system activity and, therefore, a decrease in blood pressure.
Compared to the older central-acting antihypertensives, moxonidine binds with much greater affinity to the imidazoline I1-receptor than to the α2-receptor. In contrast, clonidine binds to both receptors with equal affinity.
In addition, moxonidine may also promote sodium excretion, improve insulin resistance and glucose tolerance and protect against hypertensive target organ damage, such as kidney disease and cardiac hypertrophy.

08/11/2012

Riociguat, which relaxes pulmonary blood vessels via a novel mechanism, improved 6-minute walk distances in patients with pulmonary arterial hypertension (PAH) and in those with chronic thromboembolic pulmonary hypertension (CTEPH) in separate placebo-controlled trials, according to Hossein Ardeschir Ghofrani, MD, of University Hospital of Giessen and Marburg in Giessen, Germany